NCT06777030 Role of Exosomes in Pancreatic Cancer Progression
| NCT ID | NCT06777030 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Pancreatic Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2022-05-22 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2022-05-22 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The present pilot study is set up with the objective of identifying circulating markers in the biological fluids (blood and urine) of subjects with pancreatic carcinoma and their association with disease stage, to evaluate their potential use as predictive and diagnostic markers for this tumor of difficult early diagnosis and often inauspicious prognosis.
Eligibility Criteria
Inclusion criteria: * People with pancreatic cancer * 18 years old * Obtaining informed consent. Exclusion criteria: * Patients who do not need or cannot perform endoscopy with biopsy sampling; * patients with a previous or active neoplastic pathology, different from pancreatic neoplasia.
Contact & Investigator
Leonardo Henry Umberto Eusebi, MD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06777030 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06777030 currently recruiting?
Yes, NCT06777030 is actively recruiting participants. Contact the research team at leonardo.eusebi@unibo.it for enrollment information.
Where is the NCT06777030 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT06777030 clinical trial?
NCT06777030 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Leonardo Henry Umberto Eusebi, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.